MCID: BPL002
MIFTS: 46

Bipolar I Disorder

Categories: Mental diseases, Rare diseases, Genetic diseases

Aliases & Classifications for Bipolar I Disorder

MalaCards integrated aliases for Bipolar I Disorder:

Name: Bipolar I Disorder 12 14 69

Classifications:



External Ids:

Disease Ontology 12 DOID:14042
ICD9CM 35 296.50
SNOMED-CT 64 49468007
UMLS 69 C0236773

Summaries for Bipolar I Disorder

Disease Ontology : 12 A bipolar disorder that is characterized by at least one manic or mixed episode.

MalaCards based summary : Bipolar I Disorder is related to personality disorder and schizophrenia. An important gene associated with Bipolar I Disorder is BDNF (Brain Derived Neurotrophic Factor), and among its related pathways/superpathways are Neuroscience and Signaling in Gap Junctions. The drugs Aripiprazole and Carbamazepine have been mentioned in the context of this disorder. Affiliated tissues include brain, amygdala and cortex, and related phenotypes are behavior/neurological and muscle

Wikipedia : 72 Bipolar I disorder (BP-I; pronounced \"type one bipolar disorder\") is a bipolar spectrum disorder... more...

Related Diseases for Bipolar I Disorder

Diseases in the Bipolar Disorder family:

Bipolar Ll Disorder Bipolar I Disorder

Diseases related to Bipolar I Disorder via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 93)
id Related Disease Score Top Affiliating Genes
1 personality disorder 27.3 BDNF COMT DTNBP1 HTR1A HTR2A HTR2C
2 schizophrenia 26.9 BDNF COMT DAO DRD1 DTNBP1 HTR1A
3 bipolar disorder 11.4
4 teebi kaurah syndrome 10.6 COMT HTR2A
5 splenic abscess 10.5 HTR2A SLC6A4
6 hyperthyroxinemia 10.5 HTR2A SLC6A4
7 hemorrhagic cystitis 10.5 COMT SLC6A4
8 neurogenic bladder 10.5 HTR2A SLC6A4
9 paranoid personality disorder 10.5 HTR1A HTR2A
10 colon mucinous adenocarcinoma 10.5 BDNF COMT SLC6A4
11 rhinoscleroma 10.5 COMT NRG1
12 polyneuropathy 10.5 HTR1A HTR2A
13 chitty hall webb syndrome 10.5 COMT NRG1
14 pervasive developmental disorder 10.5 BDNF COMT SLC6A4
15 hodgkin's granuloma 10.5 HTR1A HTR2A
16 tinea pedis 10.4 HTR1A SLC6A4
17 ulcerative colitis 10.4 BDNF COMT
18 giant cell reparative granuloma 10.4 COMT NRG1
19 uterus intravascular leiomyomatosis 10.4 COMT HTR1A SLC6A4
20 anosognosia 10.4 COMT HTR1A SLC6A4
21 renpenning syndrome 10.4 COMT HTR1A SLC6A4
22 vallecula cancer 10.3 COMT HTR1A SLC6A4
23 hepatic angiomyolipoma 10.3 BDNF HTR2A SLC6A4
24 pyromania 10.3 DRD1 HTR2A SLC6A4
25 luxation of globe 10.3 HTR1A SLC6A4
26 allergic hypersensitivity disease 10.3 HTR1A HTR2A
27 acquired aneurysmal subarachnoid hemorrhage 10.2 HTR1A HTR2A SLC6A4
28 intrahepatic gall duct cancer 10.2 BDNF COMT HTR2A SLC6A4
29 chagas disease 10.2 BDNF COMT HTR2A SLC6A4
30 hereditary multiple exostoses 10.2 BDNF COMT HTR2A SLC6A4
31 chronic dacryoadenitis 10.2 BDNF COMT HTR1A SLC6A4
32 chromosome 11p13 deletion syndrome, distal 10.2 BDNF COMT HTR2A SLC6A4
33 hepatopulmonary syndrome 10.2 COMT DRD1 HTR2A
34 vascular cancer 10.1 HTR1A HTR2A
35 angiokeratoma of mibelli 10.1 HTR1A SLC6A4
36 postencephalitic parkinson disease 10.1 BDNF HTR1A HTR2A SLC6A4
37 hypoglycemic coma 10.1 BDNF HTR1A HTR2A SLC6A4
38 may-hegglin anomaly 10.0 COMT HTR1A HTR2A SLC6A4
39 schizoaffective disorder 10.0
40 autoimmune-related retinopathy and optic neuropathy 10.0 BDNF HTR1A HTR2A SLC6A4
41 atrial fibrillation, familial, 10 10.0 BDNF HTR1A HTR2A SLC6A4
42 c8 deficiency, type ii 10.0 COMT DRD1
43 anxiety disorder 10.0
44 pauci-immune glomerulonephritis with anca 9.9 BDNF COMT DRD1 HTR2A SLC6A4
45 obesity 9.9
46 attention deficit-hyperactivity disorder 9.9
47 sexual disorder 9.8 BDNF COMT DRD1 HTR2A SLC6A4
48 obsessive-compulsive disorder 9.8
49 hepatitis d 9.8 BDNF COMT HTR1A HTR2A SLC6A4
50 bladder flat intraepithelial lesion 9.8 BDNF DTNBP1 HTR1A HTR2A SLC6A4

Graphical network of the top 20 diseases related to Bipolar I Disorder:



Diseases related to Bipolar I Disorder

Symptoms & Phenotypes for Bipolar I Disorder

MGI Mouse Phenotypes related to Bipolar I Disorder:

44
id Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 9.97 ANK3 BDNF COMT DAO DRD1 DTNBP1
2 muscle MP:0005369 9.43 DRD1 DTNBP1 EGR3 HTR2A HTR2C SLC6A4
3 nervous system MP:0003631 9.4 ANK3 BDNF COMT DAO DRD1 DTNBP1

Drugs & Therapeutics for Bipolar I Disorder

Drugs for Bipolar I Disorder (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 179)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Aripiprazole Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 129722-12-9 60795
2
Carbamazepine Approved, Investigational Phase 4,Phase 3,Phase 1 298-46-4 2554
3
Coal tar Approved Phase 4 8007-45-2
4
Dopamine Approved Phase 4,Phase 3,Phase 2,Phase 1 51-61-6, 62-31-7 681
5
Olanzapine Approved, Investigational Phase 4,Phase 3 132539-06-1 4585
6
Oxcarbazepine Approved Phase 4 28721-07-5 34312
7
Valproic Acid Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 99-66-1 3121
8
Ziprasidone Approved Phase 4,Phase 3,Phase 2 146939-27-7 60854
9
Ropinirole Approved, Investigational Phase 4 91374-20-8, 91374-21-9 5095 497540
10
Risperidone Approved, Investigational Phase 4,Phase 3 106266-06-2 5073
11
Lamotrigine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 84057-84-1 3878
12
Cocaine Approved, Illicit Phase 4 50-36-2 5760 446220
13
Benzocaine Approved Phase 4 1994-09-7, 94-09-7 2337
14
Fluoxetine Approved, Vet_approved Phase 4 54910-89-3 3386
15
Methylphenidate Approved, Investigational Phase 4 113-45-1 4158
16
Infliximab Approved Phase 4,Phase 2 170277-31-3
17
Norepinephrine Approved Phase 4,Phase 3 51-41-2 439260
18
Ethanol Approved Phase 4,Phase 3,Phase 2 64-17-5 702
19
Acetylcysteine Approved, Investigational Phase 4 616-91-1 12035
20
Epinephrine Approved, Vet_approved Phase 4 51-43-4 5816
21 Racepinephrine Approved Phase 4
22
Zonisamide Approved, Investigational Phase 4 68291-97-4 5734
23
Choline Approved, Nutraceutical Phase 4 62-49-7 305
24 tannic acid Approved, Nutraceutical Phase 4
25 Antidepressive Agents Phase 4,Phase 3,Phase 2,Early Phase 1
26 Antimanic Agents Phase 4,Phase 3,Phase 2,Phase 1
27 Antipsychotic Agents Phase 4,Phase 3,Phase 2,Phase 1
28 Central Nervous System Depressants Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
29 Lithium carbonate Phase 4,Phase 3,Phase 2,Early Phase 1 554-13-2
30 Neurotransmitter Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
31 Psychotropic Drugs Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
32 Quetiapine Fumarate Phase 4,Phase 3,Phase 2 111974-72-2
33 Tranquilizing Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
34 Analgesics Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
35 Analgesics, Non-Narcotic Phase 4,Phase 3,Phase 1
36 Anticonvulsants Phase 4,Phase 3,Phase 2,Phase 1
37 Antiemetics Phase 4,Phase 3,Phase 2
38 Autonomic Agents Phase 4,Phase 3,Phase 2
39 Cytochrome P-450 CYP3A Inducers Phase 4,Phase 3,Phase 2,Phase 1
40 Diuretics, Potassium Sparing Phase 4,Phase 3,Phase 2,Phase 1
41 Dopamine Agents Phase 4,Phase 3,Phase 2,Phase 1
42 Dopamine Antagonists Phase 4,Phase 3,Phase 2,Phase 1
43 GABA Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
44 Gastrointestinal Agents Phase 4,Phase 3,Phase 2
45 Neurotransmitter Uptake Inhibitors Phase 4,Phase 3
46 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
47
Serotonin Phase 4,Phase 3,Phase 2,Phase 1 50-67-9 5202
48 Serotonin Agents Phase 4,Phase 3,Phase 2,Phase 1
49 Serotonin Antagonists Phase 4,Phase 3,Phase 2,Phase 1
50 Serotonin Uptake Inhibitors Phase 4,Phase 3

Interventional clinical trials:

(show top 50) (show all 280)

id Name Status NCT ID Phase Drugs
1 Potentiation of Quetiapine Treatment With Lithium or Aripiprazole in Bipolar 1 Nonresponders Patients Unknown status NCT01710163 Phase 4 Lithium;Aripiprazole
2 Comparative Efficacy and Acceptability of Antimanic Drugs in Acute Mania Unknown status NCT01893229 Phase 4 Lithium;Valproate;Oxcarbazepine;Quetiapine;Olanzapine;Ziprasidone
3 Efficacy and Safety of Utapine vs. Seroquel in Patients With Bipolar Mania Unknown status NCT01043679 Phase 4 Utapine;Seroquel
4 A Placebo Controlled Trial of the Dopamine D-2 Receptor Agonist Ropinirole in Treatment of 60 Patients With Refractory Bipolar Depression. Unknown status NCT00335205 Phase 4 ropinirole
5 Olanzapine Versus Active Comparator in the Treatment of Bipolar I Disorder Completed NCT00034580 Phase 4 olanzapine;risperidone
6 A Phase IV Study of the Safety and Efficacy of Aripiprazole in Combination With Lamotrigine in the Long-Term Maintenance Treatment of Patients With Bipolar I Disorder With A Recent Manic or Mixed Episode Completed NCT00277212 Phase 4 Lamotrigine + Aripiprazole;Lamotrigine + Placebo
7 Citicoline for Bipolar 1 Disorder and Cocaine Dependence Completed NCT00619723 Phase 4 Citicoline;Placebo
8 A Comparison of Olanzapine in Combination With a Mood Stabilizer vs Mood Stabilizer Alone, in Mixed Bipolar Patients Completed NCT00402324 Phase 4 olanzapine;placebo;divalproex
9 The Assessment of a Weight-Gain Agent for the Treatment of Olanzapine-Associated Anti-Obesity Agent in Patients With Schizophrenia, Schizophreniform Disorder, Schizoaffective Disorder, and Bipolar I Disorder Completed NCT00044187 Phase 4 Sibutramine
10 The Young Adult and Pediatric Bipolar Study Completed NCT00350857 Phase 4 Extended-Release Carbamazepine
11 Olanzapine Versus Placebo in the Treatment of Mania in Adolescents With Bipolar I Disorder Completed NCT00050206 Phase 4 Olanzapine;Placebo
12 Study in Adolescents With Schizophrenia or Bipolar Disorder Completed NCT00982020 Phase 4 Olanzapine
13 Olanzapine vs. Comparator and Placebo in the Treatment of Patients With Bipolar I Disorder Completed NCT00094549 Phase 4 olanzapine;divalproex sodium;placebo
14 Effects of Comorbid Personality Disorder on the Treatment of Bipolar I Disorder Completed NCT00178061 Phase 4
15 Efficacy of Combined Treatment for Young Bipolar I Disorder Completed NCT00976794 Phase 4 lithium plus carbamazepine;lithium plus valproate
16 Olanzapine Plus Carbamazepine in the Treatment of Bipolar I Mania Completed NCT00190892 Phase 4 olanzapine;carbamazepine
17 Open Label Extension Study of Licarbazepine in the Treatment of Manic Episodes of Bipolar I Disorder Completed NCT00139594 Phase 4 licarbazepine
18 A Study of Aripiprazole (Abilify) in Patients With Bipolar Mania Completed NCT00261443 Phase 4 Lithium or Valproate with placebo (PBO);Lithium or Valproate with Aripiprazole
19 A Study for Assessing Treatment of Patients Ages 10-17 With Bipolar Depression Completed NCT00844857 Phase 4 Olanzapine Fluoxetine Combination (OFC);Placebo
20 Sequential Multiple Assignment Treatment for Bipolar Disorder Completed NCT01588457 Phase 4 Lithium/Lithium Carbonate;Divalproex;Lamotrigine;Quetiapine
21 Research and Evaluation of Antipsychotic Treatment in Community Behavioral Health Organizations Completed NCT01181960 Phase 4 Risperidone long acting injectable - New Starts;Risperidone long acting injectable - Continuous Users;Paliperidone Palmitate -New and Continuous Users;Other Antipsychotics - New Starts
22 ABLE: Abilify in Bipolar Disorder for Long-term Effectiveness Completed NCT00484471 Phase 4 aripiprazole;valproate;placebo
23 Quetiapine Fumarate (Seroquel) as Mono-Therapy or Adjunct to Lithium in the Treatment of Patients With Acute Mania in Bipolar Disorder Completed NCT00672490 Phase 4 Quetiapine Fumarate;Lithium
24 Equetro for the Treatment of Mania in Children Ages 6-12 With Bipolar Disorder Completed NCT00181870 Phase 4 carbamazepine ER (Equetro)
25 Concerta in the Treatment of ADHD in Youth and Adults With Bipolar Disorder Completed NCT00181987 Phase 4 methylphenidate HCl (Concerta)
26 Study of Depakote ER for the Treatment of Mania in Children Ages 6-12 With Bipolar Disorder Completed NCT00181727 Phase 4 divalproex sodium extended release
27 Aripiprazole for the Treatment of Mania in Children and Adolescents With Bipolar Disorder Completed NCT00181779 Phase 4 aripiprazole (Abilify)
28 Lamotrigine for the Treatment of Mania in Youth Ages 6-17 With Bipolar Disorder Completed NCT00181844 Phase 4 lamotrigine
29 A Study of Infliximab for Treatment Resistant Major Depression Completed NCT00463580 Phase 4 infliximab (remicade);Placebo
30 VALID : VAlproate Versus LIthium in Bipolar Disorders Completed NCT00264173 Phase 4 Valproate sodium
31 Venlafaxine Versus Lamotrigine in the Treatment of Bipolar I/II Depression Completed NCT00188643 Phase 4 Venlafaxine and Lamotrigine
32 Efficacy of Olanzapine Monotherapy for Treatment Bipolar Ⅰ Depression Completed NCT01303601 Phase 4 olanzapine;Starch
33 Olanzapine/Fluoxetine Combination Versus Comparator in the Treatment of Bipolar I Depression Completed NCT00485771 Phase 4 Olanzapine;Fluoxetine;Lamotrigine
34 Open-Label Comparative Study of Risperidone Versus Olanzapine Versus Quetiapine for Mania in Children and Adolescents With Bipolar I and Bipolar II Disorder Completed NCT00182013 Phase 4 Risperidone;Olanzapine;Quetiapine
35 Comparing Compliance, Tolerability, Efficacy and Adverse Events in Bipolar Tients From Valproic Acid to Depakote ER Completed NCT00211250 Phase 4 Valproic Acid and Depakote ER
36 Gulf Evaluation of VAlproate (Depakine Chrono) in maNia Study Completed NCT00477373 Phase 4 depakine chrono
37 The Efficacy and Safety of Oral Oxcarbazepine 300-1200 mg/Day as Adjuvant Therapy in the Treatment of Bipolar Disorder I or II This Study is Not Being Conducted in the United States. Completed NCT00154323 Phase 4 Oxcarbazepine
38 DB/Maintenance of Equetro (Carbamazepine) in Children With Acute Manic or Mixed Bipolar 1 Disorder Recruiting NCT02623504 Phase 4 Carbamazepine;Placebo
39 Creatine Monohydrate as Adjuvant Therapy for Bipolar Depression Recruiting NCT01655030 Phase 4
40 Efficacy of rTMS in Bipolar I Depression Recruiting NCT02749006 Phase 4
41 Gao NARASD Lithium Study Recruiting NCT02909504 Phase 4 Lithium
42 Open-Label Study of N-Acetylcysteine in Children and Adolescents 5-17 With Bipolar Spectrum Disorders Recruiting NCT02357290 Phase 4 Open-label Treatment with N-Acetylcysteine
43 Clinical Medication Development for Bipolar Disorder and Alcohol Use Disorders Recruiting NCT02582905 Phase 4 Placebo;Citicoline;Pregnenolone
44 16-week Comparative Effectiveness Trial of Lamotrigine vs. Fluoxetine for Bipolar Depression Recruiting NCT02389712 Phase 4 Lamotrigine;Fluoxetine
45 Neurofunctional and Neurochemical Markers of Treatment Response in Bipolar Disorder Active, not recruiting NCT00608075 Phase 4 lithium;Lithium
46 Open-Label Study of Latuda for the Treatment of Mania in Children and Adolescents 6-17 Years Old Suspended NCT01932541 Phase 4 Latuda (Lurasidone)
47 Seroquel in Acute Mania: Study to Investigate if Valproate Add-On Therapy is Superior to Quetiapine Monotherapy in Acutely Manic Patients Terminated NCT00139074 Phase 4 Quetiapine fumarate;sodium valproate
48 Invega (Paliperidone) for the Treatment of Mania in Children and Adolescents Ages 6-17 With Bipolar Disorder Terminated NCT00592358 Phase 4 paliperidone
49 Open-label Adjunctive Zonisamide for Bipolar Disorder Terminated NCT00047567 Phase 4 zonisamide
50 Study of the Efficacy of Adjunctive Lithium Treatment for the Treatment of Psychotic Mania Withdrawn NCT01495156 Phase 4 Lithium treatment in combination with a SGA (Second Generation Antipsychotic);Placebo/Adjunctive SGA treatment

Search NIH Clinical Center for Bipolar I Disorder

Genetic Tests for Bipolar I Disorder

Anatomical Context for Bipolar I Disorder

MalaCards organs/tissues related to Bipolar I Disorder:

39
Brain, Amygdala, Cortex, Bone, Cingulate Cortex, Prefrontal Cortex, Testes

Publications for Bipolar I Disorder

Articles related to Bipolar I Disorder:

(show top 50) (show all 637)
id Title Authors Year
1
Efficacy and safety of sublingual ramelteon as an adjunctive therapy in the maintenance treatment of bipolar I disorder in adults: A phase 3, randomized controlled trial. ( 28662460 )
2017
2
Long-term safety and tolerability of asenapine: A double-blind, uncontrolled, long-term extension trial in adults with an acute manic or mixed episode associated with bipolar I disorder. ( 27755982 )
2017
3
Neurocognition in patients with psychotic and non-psychotic bipolar I disorder. A comparative study with individuals with schizophrenia. ( 28709024 )
2017
4
Epidemiology of DSM-5 bipolar I disorder: Results from the National Epidemiologic Survey on Alcohol and Related Conditions - III. ( 27814503 )
2017
5
The safety and tolerability of cariprazine in patients with manic or mixed episodes associated with bipolar I disorder: A 16-week open-label study. ( 28843918 )
2017
6
Plasma interleukin-6 in remitted early bipolar I disorder and subjects at high-risk for bipolar disorder. ( 28365164 )
2017
7
Solar insolation in springtime influences age of onset of bipolar I disorder. ( 28722128 )
2017
8
Randomized, Double-Blind, Placebo-Controlled Trial of Asenapine Maintenance Therapy in Adults With an Acute Manic or Mixed Episode Associated With Bipolar I Disorder. ( 28946761 )
2017
9
Autistic and schizotypal traits and global functioning in bipolar I disorder. ( 27736738 )
2017
10
Bipolar I disorder in remission vs. schizophrenia in remission: Is there a difference in burden? ( 27816846 )
2017
11
Association between the zinc finger protein 804A (ZNF804A) gene and the risk of schizophrenia and bipolar I disorder across diagnostic boundaries. ( 28544350 )
2017
12
Biological dysrhythm in remitted bipolar I disorder. ( 28559123 )
2017
13
Effectiveness of the Dader Method for Pharmaceutical Care on Patients with Bipolar I Disorder: Results from the EMDADER-TAB Study. ( 28025928 )
2017
14
Lurasidone in combination with lithium or valproate for the maintenance treatment of bipolar I disorder. ( 28689688 )
2017
15
Increased cooperative behavior across remitted bipolar I disorder and major depression: Insights utilizing a behavioral economic trust game. ( 27868424 )
2017
16
Cortisol levels in fingernails, neurocognitive performance and clinical variables in euthymic bipolar I disorder. ( 28345388 )
2017
17
Clinical pharmacokinetic interactions between lamotrigine and hormonal contraceptives in bipolar I disorder. ( 28191687 )
2017
18
Increased hippocampal, thalamus and amygdala volume in long-term lithium-treated bipolar I disorder patients compared with unmedicated patients and healthy subjects. ( 28239952 )
2017
19
Facial emotion labeling in unaffected offspring of adults with bipolar I disorder. ( 27792963 )
2017
20
Initial symptom severity of bipolar I disorder and the efficacy of olanzapine: a meta-analysis of individual participant data from five placebo-controlled studies. ( 28939419 )
2017
21
Dysregulation of objectively assessed 24-hour motor activity patterns as a potential marker for bipolar I disorder: results of a community-based family study. ( 28892068 )
2017
22
Preventive Effects of Lamotrigine in Bipolar II Versus Bipolar I Disorder. ( 28817765 )
2017
23
Comparison of metabolic syndrome prevalence in patients with schizophrenia and bipolar I disorder. ( 28927969 )
2017
24
Personality disorder symptom severity predicts onset of mood episodes and conversion to bipolar I disorder in individuals with bipolar spectrum disorder. ( 28368159 )
2017
25
The CACNA1C risk allele rs1006737 is associated with age-related prefrontal cortical thinning in bipolar I disorder. ( 28398341 )
2017
26
Neurocognitive function in clinically stable individuals with long-term bipolar I disorder: Comparisons with schizophrenia patients and controls. ( 28433073 )
2017
27
Olfactory Neuroepithelial Neural Progenitor Cells from Subjects with Bipolar I Disorder. ( 28469524 )
2017
28
A Study on the Association of Interleukin-1 Cluster with Genetic Risk in Bipolar I Disorder in Iranian Patients: A Case-control Study. ( 28129679 )
2016
29
Neuropsychological study of IQ scores in offspring of parents with bipolar I disorder. ( 27855540 )
2016
30
Is history of suicidal behavior related to social support and quality of life in outpatients with bipolar I disorder? ( 28029441 )
2016
31
Unseen positive and negative affective information influences social perception in bipolar I disorder and healthy adults. ( 26745436 )
2016
32
A pilot study of a combined group and individual functional remediation program for patients with bipolar I disorder. ( 26800305 )
2016
33
Neuroprogression and episode recurrence in bipolar I disorder: A study of gray matter volume changes in first-episode mania and association with clinical outcome. ( 27759214 )
2016
34
Feasibility of a psychoeducational family intervention for people with bipolar I disorder and their relatives: Results from an Italian real-world multicentre study. ( 26590513 )
2016
35
History of Lifetime suicide attempt in bipolar I disorder: its correlates and effect on illness course. ( 27854557 )
2016
36
Relationship Between Temperament and Character Traits, Mood, and Medications in Bipolar I Disorder. ( 27733949 )
2016
37
Borderline personality disorder, but not euthymic bipolar I disorder, is associated with prolonged post-error slowing in sensorimotor performance. ( 27016660 )
2016
38
Bipolar II compared with bipolar I disorder: baseline characteristics and treatment response to quetiapine in a pooled analysis of five placebo-controlled clinical trials of acute bipolar depression. ( 26973704 )
2016
39
Levels of mania and cognitive performance two years after ECT in patients with bipolar I disorder - results from a follow-up study. ( 27423347 )
2016
40
Admission-Based Prevalence of Schizophrenia, Schizoaffective Disorder and Bipolar I Disorder in a Catchment Area in Sinop, Turkey. ( 27711935 )
2016
41
Lithium prophylaxis during pregnancy and the postpartum period in women with lithium-responsive bipolar I disorder. ( 26790685 )
2016
42
Relationships Between Altered Functional Magnetic Resonance Imaging Activation and Cortical Thickness in Patients With Euthymic Bipolar I Disorder. ( 27990494 )
2016
43
Effects of Omega-3 Supplement in the Treatment of Patients with Bipolar I Disorder. ( 27280013 )
2016
44
Sleep in Adolescents With Bipolar I Disorder: Stability and Relation to Symptom Change. ( 27472039 )
2016
45
Demographic and clinical characteristics associated with comorbid cannabis use disorders (CUDs) in hospitalized patients with bipolar I disorder. ( 26773991 )
2016
46
Cytokines, brain-derived neurotrophic factor and C-reactive protein in bipolar I disorder - Results from a prospective study. ( 26994434 )
2016
47
Cabergoline can induce mania with psychotic features in bipolar I disorder: a case report. ( 27520906 )
2016
48
Hippocampal subfield volumes in short- and long-term lithium-treated patients with bipolar I disorder. ( 27237705 )
2016
49
Increased DNA and RNA damage by oxidation in patients with bipolar I disorder. ( 27505230 )
2016
50
Perceptions of social dominance through facial emotion expressions in euthymic patients with bipolar I disorder. ( 26995253 )
2016

Variations for Bipolar I Disorder

Expression for Bipolar I Disorder

Search GEO for disease gene expression data for Bipolar I Disorder.

Pathways for Bipolar I Disorder

GO Terms for Bipolar I Disorder

Cellular components related to Bipolar I Disorder according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 plasma membrane GO:0005886 9.96 ANK3 COMT DRD1 DTNBP1 GRID1 HTR1A
2 integral component of plasma membrane GO:0005887 9.8 DRD1 HTR1A HTR2A HTR2C NRG1 SLC6A4
3 synapse GO:0045202 9.67 ANK3 DTNBP1 GRID1 NRG1
4 dendrite GO:0030425 9.46 ANK3 COMT HTR2A NRG1
5 postsynaptic membrane GO:0045211 9.26 ANK3 COMT DTNBP1 GRID1
6 axon GO:0030424 9.02 ANK3 COMT DTNBP1 HTR2A NRG1

Biological processes related to Bipolar I Disorder according to GeneCards Suite gene sharing:

(show all 21)
id Name GO ID Score Top Affiliating Genes
1 positive regulation of gene expression GO:0010628 9.77 ANK3 DRD1 DTNBP1 NRG1 SLC6A4
2 response to drug GO:0042493 9.72 COMT DRD1 HTR2A HTR2C SLC6A4
3 locomotory behavior GO:0007626 9.71 DRD1 HTR2C NRG1
4 circadian rhythm GO:0007623 9.7 EGR3 PER3 SLC6A4
5 memory GO:0007613 9.65 DRD1 HTR2A SLC6A4
6 synapse assembly GO:0007416 9.63 BDNF DRD1 NRG1
7 neuronal action potential GO:0019228 9.6 ANK3 DRD1
8 positive regulation of cytosolic calcium ion concentration involved in phospholipase C-activating G-protein coupled signaling pathway GO:0051482 9.59 DRD1 HTR2C
9 regulation of dopamine secretion GO:0014059 9.58 DTNBP1 HTR2A
10 behavioral response to cocaine GO:0048148 9.58 DRD1 HTR2A
11 temperature homeostasis GO:0001659 9.57 DRD1 HTR2A
12 vasoconstriction GO:0042310 9.56 HTR1A SLC6A4
13 dopamine metabolic process GO:0042417 9.55 COMT DRD1
14 regulation of dopamine metabolic process GO:0042053 9.51 DRD1 HTR1A
15 regulation of behavior GO:0050795 9.49 HTR1A HTR2A
16 regulation of hormone secretion GO:0046883 9.43 HTR1A HTR2A
17 behavioral fear response GO:0001662 9.43 DRD1 HTR1A HTR2C
18 positive regulation of phosphatidylinositol biosynthetic process GO:0010513 9.4 HTR2A HTR2C
19 phospholipase C-activating serotonin receptor signaling pathway GO:0007208 9.16 HTR2A HTR2C
20 behavior GO:0007610 9.13 HTR1A HTR2A HTR2C
21 serotonin receptor signaling pathway GO:0007210 8.8 HTR1A HTR2A HTR2C

Molecular functions related to Bipolar I Disorder according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 signal transducer activity GO:0004871 9.62 DRD1 HTR1A HTR2A HTR2C
2 neurotransmitter receptor activity GO:0030594 9.33 HTR1A HTR2A HTR2C
3 1-(4-iodo-2,5-dimethoxyphenyl)propan-2-amine binding GO:0071886 9.26 HTR2A HTR2C
4 G-protein coupled serotonin receptor activity GO:0004993 9.13 HTR1A HTR2A HTR2C
5 serotonin binding GO:0051378 8.8 HTR1A HTR2A HTR2C

Sources for Bipolar I Disorder

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....